| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
19.31(B) |
| Last
Volume: |
1,621,262 |
Avg
Vol: |
1,396,245 |
| 52
Week Range: |
$92.79 - $147.2 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 509 |
| Guru Rank Value : 3.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
7,330 |
7,330 |
| Total Buy Value |
$0 |
$0 |
$991,672 |
$991,672 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
315 |
22,201 |
| Total Sell Value |
$0 |
$0 |
$35,545 |
$4,541,175 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
16 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Desouza Francis A |
President and CEO |
• • – |
2016-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
11,728 |
119,143 |
|
- |
|
| Stapley Marc |
EVP & Chief Administrative Ofc |
• • – |
2016-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,496 |
36,545 |
|
- |
|
| Ronaghi Mostafa |
Sr VP & CTO |
• • – |
2016-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,910 |
61,417 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2016-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,542 |
42,090 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2016-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,496 |
55,988 |
|
- |
|
| Bouchard Michel |
Chief Accounting Officer |
• • – |
2016-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,737 |
23,208 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2016-12-01 |
4 |
AS |
$133.30 |
$399,900 |
D/D |
(3,000) |
51,492 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-11-14 |
4 |
AS |
$136.34 |
$81,803 |
D/D |
(600) |
16,465 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-11-14 |
4 |
OE |
$71.09 |
$42,654 |
D/D |
600 |
17,065 |
|
- |
|
| Desouza Francis A |
President and CEO |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$162,029 |
D/D |
(1,182) |
107,415 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$337,080 |
D/D |
(2,459) |
485,602 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$95,545 |
D/D |
(697) |
54,492 |
|
- |
|
| Ronaghi Mostafa |
Sr VP & CTO |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$60,315 |
D/D |
(440) |
57,507 |
|
- |
|
| Stapley Marc |
EVP & Chief Administrative Ofc |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$95,545 |
D/D |
(697) |
32,049 |
|
- |
|
| Henry Christian O |
EVP & Chief Commercial Officer |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$89,102 |
D/D |
(650) |
18,326 |
|
- |
|
| Orpin Tristan |
EVP Clinical Genomics |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$95,545 |
D/D |
(697) |
118,259 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$48,252 |
D/D |
(352) |
39,548 |
|
- |
|
| Bouchard Michel |
Chief Accounting Officer |
• • – |
2016-11-07 |
4 |
D |
$137.08 |
$70,048 |
D/D |
(511) |
20,471 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-10-07 |
4 |
AS |
$184.07 |
$110,613 |
D/D |
(600) |
16,465 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-10-07 |
4 |
OE |
$71.09 |
$42,654 |
D/D |
600 |
17,065 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2016-10-04 |
4 |
AS |
$182.38 |
$21,156 |
D/D |
(116) |
39,900 |
|
- |
|
| Epstein Robert S |
Director |
• • – |
2016-09-20 |
4 |
AS |
$174.29 |
$52,287 |
D/D |
(300) |
6,924 |
|
- |
|
| Stapley Marc |
EVP & Chief Administrative Ofc |
• • – |
2016-09-15 |
4 |
AS |
$170.08 |
$219,543 |
D/D |
(1,270) |
32,746 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-09-14 |
4 |
AS |
$170.40 |
$102,748 |
D/D |
(600) |
16,465 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-09-14 |
4 |
OE |
$71.09 |
$42,654 |
D/D |
600 |
17,065 |
|
- |
|
1655 Records found
|
|
Page 37 of 67 |
|
|
6.12 (4.85%) 
